Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

This genetic research study uses whole exome sequencing — reading nearly all the protein-coding parts of a person's DNA — to look for inherited genetic differences that may explain why some breast cancer patients develop heart failure (weakened heart muscle) after treatment with anthracycline chemotherapy and the drug bevacizumab. **You may be eligible if...** - You are of European American or African American ancestry and have DNA samples available - You are designated as a case (you developed heart failure — specifically a significant drop in your heart's pumping function after treatment) or a control (you completed a full course of anthracycline and bevacizumab treatment without developing heart failure) **You may NOT be eligible if...** - You do not meet the above ancestry, DNA availability, and case/control designation criteria Talk to your doctor to see if this trial is right for you.